Which one of the following therapies would be safe in a patient with pulmonary tuberculosis having markedly abnormal liver function :
## **Core Concept**
The management of pulmonary tuberculosis (TB) in patients with abnormal liver function requires careful selection of antitubercular drugs to avoid further hepatotoxicity. The first-line antitubercular drugs, such as isoniazid, rifampicin, and pyrazinamide, are known to have hepatotoxic potential.
## **Why the Correct Answer is Right**
The correct answer, , likely refers to a drug or combination that is less hepatotoxic. Ethambutol is an antitubercular drug that is not primarily metabolized by the liver and has a lower risk of hepatotoxicity compared to isoniazid, rifampicin, and pyrazinamide. Therefore, in a patient with markedly abnormal liver function, ethambutol would be a safer option.
## **Why Each Wrong Option is Incorrect**
* **Option A:** Isoniazid is known for its hepatotoxic potential, making it a risky choice for patients with abnormal liver function.
* **Option B:** Rifampicin also carries a risk of hepatotoxicity and is not the best choice in this scenario.
* **Option D:** Pyrazinamide has significant hepatotoxic potential, especially in patients with pre-existing liver disease.
## **Clinical Pearl / High-Yield Fact**
In patients with pulmonary tuberculosis and abnormal liver function, it is crucial to monitor liver enzymes and consider using drugs with lower hepatotoxic potential, such as ethambutol, while still aiming for an effective antitubercular regimen.
## **Correct Answer:** .